Business
Evotec SE to Announce Results for The First Nine Months 2025 on 05 November 2025
HAMBURG, DE / ACCESS Newswire / October 29, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its interim statement for the first nine months 2025 on Wednesday, ...
About this update from Evotec Se
[{"type":"text","content":"HAMBURG, DE / ACCESS Newswire / October 29, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its interim statement for the first nine months 2025 on Wednesday, 05 November 2025.","length":264,"tagName":"p"},{"type":"text","content":"The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English.","length":163,"tagName":"p"},{"type":"text","content":"Webcast details","length":15,"tagName":"p"},{"type":"text","content":"Date: Wednesday, 05 November 2025","length":33,"tagName":"p"},{"type":"text","content":"Time: 2.00 pm CET (01.00 pm GMT, 08.00 am EST)","length":46,"tagName":"p"},{"type":"text","content":"To join the audio webcast and to access the presentation slides, please register via this link.","length":95,"tagName":"p"},{"type":"text","content":"The on-demand version of the webcast will be available on our website: Financial Publications - Evotec.","length":103,"tagName":"p"},{"type":"text","content":"Conference call details","length":23,"tagName":"p"},{"type":"text","content":"To join via phone, please pre-register via this link . You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.","length":194,"tagName":"p"},{"type":"text","content":"A simultaneous slide presentation for participants dialling in via phone is available under this link.","length":102,"tagName":"p"},{"type":"text","content":"About Evotec SEEvotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision.","length":296,"tagName":"p"},{"type":"text","content":"Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling.","length":203,"tagName":"p"},{"type":"text","content":"With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcar...